Receptor mediated targeting of EGF-conjugated alginate-PAMAM nanoparticles to lung adenocarcinoma: 2D/3D in vitro and in vivo evaluation

Basit Öğe Kaydı
dc.authoridIlhan Ayisigi, Esra/0000-0003-1880-4261
dc.contributor.authorIlhan-Ayisigi, Esra
dc.contributor.authorSaglam-Metiner, Pelin
dc.contributor.authorSanci, Ebru
dc.contributor.authorBakan, Buket
dc.contributor.authorYildirim, Yeliz
dc.contributor.authorBuhur, Aylin
dc.contributor.authorYavasoglu, Altug
dc.date.accessioned2024-08-31T07:46:55Z
dc.date.available2024-08-31T07:46:55Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractCarboplatin (cis-diamine (1,1-cyclobutandicarboxylaso)-platinum (II)) is a second-generation antineoplastic drug, which is widely used for chemotherapy of lung, colon, breast, cervix, testicular and digestive system cancers. Although preferred over cisplatin due to the lower incidence of nephrotoxicity and ototoxicity, efficient carboplatin delivery remains as a major challenge. In this study, carboplatin loaded alginate- poly(amidoamine) (PAMAM) hybrid nanoparticles (CAPs) with mean sizes of 192.13 +/- 4.15 nm were synthesized using a microfluidic platform, then EGF was conjugated to the surface of CAPs (EGF-CAPs) for the receptor-targeted delivery. Hence, increased FITC+ cell counts were observed in A549 spheroids after EGF-CAP treatment compared to CAP in the 3D cellular uptake study. As such, the cytotoxicity of EGF-CAP was approximately 2-fold higher with an IC50 value of 35.89 +/- 10.37 mu g/mL compared to the CAPs in A549 spheroids. Based on in vivo experimental animal model, anti-tumor activities of the group treated with CAP decreased by 61 %, whereas the group treated with EGF-CAP completely recovered. Additionally, EGF-CAP application was shown to induce apoptotic cell death. Our study provided a new strategy for designing a hybrid nanoparticle for EGFR targeted carboplatin delivery with improved efficacy both in vitro and in vivo applications.en_US
dc.description.sponsorshipEge University, Scientific Research Foundation [FGA -2020-21665]en_US
dc.description.sponsorshipThis study was supported by Ege University, Scientific Research Foundation through FGA -2020-21665.en_US
dc.identifier.doi10.1016/j.ijbiomac.2024.129758
dc.identifier.issn0141-8130
dc.identifier.issn1879-0003
dc.identifier.pmid38286366en_US
dc.identifier.scopus2-s2.0-85183578280en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijbiomac.2024.129758
dc.identifier.urihttps://hdl.handle.net/11454/104242
dc.identifier.volume261en_US
dc.identifier.wosWOS:001174261800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofInternational Journal of Biological Macromoleculesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectAlginateen_US
dc.subjectPamam Dendrimeren_US
dc.subjectMicrofluidic Synthesisen_US
dc.subjectCarboplatinen_US
dc.subjectTargeted Drug Deliveryen_US
dc.subjectIn Vivo Lung Cancer Modelen_US
dc.titleReceptor mediated targeting of EGF-conjugated alginate-PAMAM nanoparticles to lung adenocarcinoma: 2D/3D in vitro and in vivo evaluationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu